Media headlines about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.8481587962074 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Mount Dora boy among first to receive approved gene therapy drug for eye disease (orlandosentinel.com)
- Hot Stock’s Alert – Spark Therapeutics, (NASDAQ: ONCE) (stocksnewstimes.com)
- Morning Stock Review: Spark Therapeutics, Inc. (ONCE) stock price is at $65.37 on volume of 364285 shares with … – Nasdaq Express (nasdaqexpress.com)
- Spark Therapeutics, Inc. (ONCE) Swings Under Volatility … – Investing News Update (investingbizz.com)
- Spark Therapeutics Getting Closer To Key Technical Benchmark (investors.com)
Spark Therapeutics (NASDAQ ONCE) opened at $63.09 on Monday. The company has a market capitalization of $2,348.02, a PE ratio of -8.16 and a beta of 2.82. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.
Several research firms recently weighed in on ONCE. Raymond James Financial reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Spark Therapeutics in a research note on Thursday, December 7th. BMO Capital Markets set a $73.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. Barclays reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Finally, ValuEngine lowered Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company. Spark Therapeutics has a consensus rating of “Buy” and a consensus target price of $70.58.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.